Neuphoria Therapeutics ( (NEUP) ) has released a notification of late filing.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neuphoria Therapeutics Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The primary reason for the delay is the need for additional time to compile and analyze supporting documentation, as well as to allow the company’s independent registered public accounting firm to complete its review. The company anticipates filing the report within the five-day extension period provided under Rule 12b-25. Neuphoria Therapeutics does not expect any significant changes in its financial results compared to the corresponding period last year. The notification was signed by Spyridon Papapetropoulos, the Chief Executive Officer, indicating ongoing compliance efforts.
The most recent analyst rating on (NEUP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page.
More about Neuphoria Therapeutics
Average Trading Volume: 36,484
Technical Sentiment Signal: Hold
Current Market Cap: $8.77M
For a thorough assessment of NEUP stock, go to TipRanks’ Stock Analysis page.